Perrigo Company plc Restructuring Reserve, Foreign Currency Translation Gain (Loss)
Perrigo Company plc (PRGO) reported Restructuring Reserve, Foreign Currency Translation Gain (Loss) of -$1.40 million for the 3-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Restructuring and Related Activities
us-gaap:RestructuringReserveTranslationAdjustment · last filed 2026-08-05
- Perrigo Company plc restructuring reserve, foreign currency translation gain (loss) for the quarter ending 2026-06-27 was -$1.40M.
- Perrigo Company plc restructuring reserve, foreign currency translation gain (loss) for the quarter ending 2025-09-27 was -$100.00K.
- Perrigo Company plc restructuring reserve, foreign currency translation gain (loss) for the quarter ending 2025-06-28 was $0.00.
| Period end | Restructuring Reserve, Foreign Currency Translation Gain (Loss) 3 month | Restructuring Reserve, Foreign Currency Translation Gain (Loss) 3 month as first filed | Restructuring Reserve, Foreign Currency Translation Gain (Loss) 6 month | Restructuring Reserve, Foreign Currency Translation Gain (Loss) 9 month |
|---|---|---|---|---|
| 2026-06-27 | -$1.40M 10-Q · filed 2026-08-05 | -$3.30M 10-Q · filed 2026-08-05 | ||
| 2025-09-27 | -$100.00K 10-Q · filed 2025-11-05 | -$100.00K derived: sum of 2 quarters · filed 2026-08-05 | $5.20M 10-Q · filed 2025-11-05 | |
| 2025-06-28 | $0.00 10-Q · filed 2026-08-05 | -$300.00K 10-Q · filed 2025-08-06 | $5.40M 10-Q · filed 2026-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |